Template:Comparison of early clinical experience with antiestrogens for advanced breast cancer
Jump to navigation
Jump to search
Template documentation
| Antiestrogen | Dosage | Year(s) | Response rate | Toxicity |
|---|---|---|---|---|
| Template:No selflink | 500–4,500 mg/day | 1960 | 25% | Acute psychotic episodes |
| Template:No selflink | 100–300 mg/day | 1964–1974 | 34% | Fears of cataracts |
| Template:No selflink | 180–240 mg/day | 1976 | 31% | Cataracts, ichthyosis, photophobia |
| Template:No selflink | 20–40 mg/day | 1971–1973 | 31% | Transient thrombocytopeniaa |
| Footnotes: a = "The particular advantage of this drug is the low incidence of troublesome side effects (25)." "Side effects were usually trivial (26)." Sources: [1][2] | ||||
References
- ↑ Jensen EV, Jordan VC (June 2003). "The estrogen receptor: a model for molecular medicine". Clin. Cancer Res. 9 (6): 1980–9. PMID 12796359.
- ↑ Howell, Anthony; Jordan, V. Craig (2013). "Adjuvant Antihormone Therapy". In Craig, Jordan V. (ed.). Estrogen Action, Selective Estrogen Receptor Modulators And Women's Health: Progress And Promise. World Scientific. pp. 229–254. doi:10.1142/9781848169586_0010. ISBN 978-1-84816-959-3.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |